The Wisconsin Alzheimer’s Institute is committed to health equity and to improving the quality of life of people living with Alzheimer’s disease or other dementia and their families. Through research initiatives, statewide memory clinic development, education and public health programs, we identify and provide strategies to reduce dementia risk and offer access to effective care. We invite you to join us in building a future to remember.
Thank you NBC15 for featuring the guide and Dr. Mora Pinzon's contributions.
Art Walaszek, MD, public health leader for WAI, was a guest on WPR to discuss the Alzheimer's disease drug aducanumab and its approval by the FDA.
On June 7, the U.S. Food and Drug Administration (FDA) approved the drug aducanumab for the treatment of Alzheimer’s disease. Read a breakdown on what this means for people living with Alzheimer's disease and family caregivers.
- More WAI News posts